Abstract

Oxidized LDL (oxLDL) increase in patients affected by type-2 diabetes, obesity, and metabolic syndrome. Likewise, insulin resistance, an impaired responsiveness of target tissues to insulin, is associated with those pathological conditions. To investigate a possible causal relationship between oxLDL and the onset of insulin resistance, we evaluated the response to insulin of 3T3-L1 adipocytes treated with oxLDL. We observed that oxLDL inhibited glucose uptake (-40%) through reduced glucose transporter 4 (GLUT4) recruitment to the plasma membrane (-70%), without affecting GLUT4 gene expression. These findings were associated to the impairment of insulin signaling. Specifically, in oxLDL-treated cells insulin receptor (IR) substrate-1 (IRS-1) was highly degraded likely because of the enhanced Ser(307)phosphorylation. This process was largely mediated by the activation of the inhibitor of kappaB-kinase beta (IKKbeta) and the c-Jun NH(2)-terminal kinase (JNK). Moreover, the activation of IKKbeta positively regulated the nuclear content of nuclear factor kappaB (NF-kappaB), by inactivating the inhibitor of NF-kappaB (IkappaBalpha). The activated NF-kappaB further impaired per se GLUT4 functionality. Specific inhibitors of IKKbeta, JNK, and NF-kappaB restored insulin sensitivity in adipocytes treated with oxLDL. These data provide the first evidence that oxLDL, by activating serine/threonine kinases, impaired adipocyte response to insulin affecting pathways involved in the recruitment of GLUT4 to plasma membranes (PM). This suggests that oxLDL might participate in the development of insulin resistance.

Highlights

  • Oxidized LDL increase in patients affected by type-2 diabetes, obesity, and metabolic syndrome

  • We demonstrated that the activity of Oxidized LDL (oxLDL) on 3T3-L1 cells required the internalization of the lipoproteins through the scavenger receptor CD36

  • The inhibition of both inhibitor of kB-kinase b (IKKb) and Jun NH2-terminal kinase (JNK) by their specific inhibitors 15d-prostaglandin J2 and SP600125 prevented the phosphorylation at Ser307 of insulin receptor substrate (IRS)-1 and the functional alterations induced in adipocytes by oxLDL

Read more

Summary

Introduction

Oxidized LDL (oxLDL) increase in patients affected by type-2 diabetes, obesity, and metabolic syndrome. Specific inhibitors of IKKb, JNK, and NF-kB restored insulin sensitivity in adipocytes treated with oxLDL These data provide the first evidence that oxLDL, by activating serine/threonine kinases, impaired adipocyte response to insulin affecting pathways involved in the recruitment of GLUT4 to plasma membranes (PM). In response to insulin, IRS-1 is phosphorylated on specific phosphotyrosine binding domains, which can couple IRS-1 to activated IR, and recruit a number of signal transducers, including phosphatidyl inositol 3-kinase [17, 18] This leads, through a complex mechanism, to the phosphorylation and activation of Akt, Abbreviations: 15d-PGJ2, 15-deoxy-D12,14-prostaglandin J2; CTR, control; GLUT4, glucose transporter 4; IkBs, inhibitory kB proteins; IKKb, inhibitor of kappa B kinase b; IR, insulin receptor; IRS, insulin receptor substrate; JNK, c-Jun NH2-terminal kinase; NF-kB, nuclear factor kB; oxLDL, oxidized LDL; PM, plasma membranes; 2-DG, 2-deoxyglucose; ROS, reactive oxygen species. To our knowledge, no data are available regarding the effects of oxLDL on the response of adipocytes to insulin

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call